-
-
Overview
-
E7820 (E-7820) is a novel and potent angiogenesis inhibitor and α2 integrin inhibitor with anticancer activity. It decreases integrin-α2 expression and is currently undergoing clinical trials. It is a small molecule and aromatic sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis. The combination of E7820 with erlotinib is an alternative strategy to overcome erlotinib resistance in NSCLC by enhancement of the anti-angiogenic activity of E7820.
Please contact us at for specific academic pricing.
-
- Properties
-
Overview